Hepatocellular-cholangiocarcinoma with sarcomatous change: Clinicopathological features and outcomes
Ye-Rong Qian a , b , Na Jiang c , Peng Liu a , b , Xu-Feng Zhang a , b , Xue-Min Liu a , b , Yi Lv a , b , Jun-Xi Xiang a , b , ∗
a Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University, No. 277 West Yan-ta Road, Xi’an 710061, China
b National Local Joint Engineering Research Center for Precision Surgery and Regenerative Medicine, First Affiliated Hospital of Xi’an Jiaotong University,
Xi’an 710061, China
c Department of Pathology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
∗ Corresponding author at: Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University, No. 277 West Yan-ta Road, Xi’an 710061, China.
E-mail address: xjx722@163.com (J.-X. Xiang).
Abstract：Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare type of cancer, accounting for 0.4%-14.2% of hepato-carcinoma. Hepatic sarcoma is only less than 2% of primary malignant liver tumors. Thus, sarcomatoid cHCC-CCA is extremely rare. To the best of our knowledge, only twenty-six cases had been reported in the literature [1-19]. Consensus cannot be reached due to the difficulty of preoperative pathological diagnosis and disagreement for the selection of the treatment. Therefore, clinicopathological features and outcome data about sarcomatoid cHCC-CCA are essential for diagnosis and treatment. We reported in this article three cases with clinical data and prognostic analysis, and summarized 26 cases of sarcomatoid cHCC-CCA from published literatures.
引用本文:
. [J]. Hepatobiliary Pancreat Dis Int, 2021, 20(6): 574-578.
Qian YR, Jiang N, Liu P, Zhang XF, Liu XM, Lv Y, Xiang JX. Hepatocellular-cholangiocarcinoma with sarcomatous change: Clinicopathological features and outcomes. Hepatobiliary Pancreat Dis Int, 2021, 20(6): 574-578.
2021, Vol. 20 
